IBRANCE is switching from capsules to tablets

Why is IBRANCE switching from capsules to tablets?
As part of our ongoing commitment to patients, Pfizer routinely looks for opportunities to better address patient needs and preferences. The IBRANCE tablet formulation offers patients:
  • Increased flexibility: Patients can take IBRANCE tablets with or without food, and they can be coadministered with proton pump inhibitors (PPIs) or antacids
  • Dose tracking: Tablets come in weekly blister packs that are designed to help patients track their treatment cycles
  • Addresses dietary concerns: The tablet formulation does not contain lactose (dairy) or gelatin
Please specify "IBRANCE tablets" on all IBRANCE prescriptions, so patients receive this formulation.
No action should be needed on your patients’ part. There is no change to the active ingredient (palbociclib), available dosage strengths (125 mg, 100 mg, 75 mg), or dosing schedule. See below for some important differences of which you should be aware.
Here’s what’s changing:
Capsules and tablets shown are not actual size.
If the individual NDC codes are unavailable for selection at your practice, please specify the dosage and “IBRANCE tablets” on all IBRANCE prescriptions.
FAQs about the IBRANCE tablets
When will my patients begin receiving IBRANCE in tablet form?
Beginning in April 2020, please specify "IBRANCE tablets" on all IBRANCE prescriptions, so patients receive the new formulation. It may take time for some pharmacies to fully transition from capsules to tablets. If the pharmacy is unable to fill a patient's prescription for tablets, a pharmacist may contact you for approval to fill with IBRANCE capsules. If this does occur, patients should be reminded that capsules have the same active ingredient as tablets, and capsules are to be taken with food.
What are the differences between IBRANCE capsules and IBRANCE tablets?
The formulations of IBRANCE are bioequivalent and contain the same active ingredient. However, IBRANCE tablets can be taken with or without food, are film-coated, and can be coadministered with PPIs or antacids.
How will this transition affect the dosing for IBRANCE?
The dosage strengths of IBRANCE will stay the same. You can continue prescribing 125 mg, 100 mg, and 75 mg doses but in tablet form. Each dosage strength of IBRANCE tablets is designed to look different—they vary in tablet shape, size, and/or color. The tablets will follow the same treatment schedule as the capsules—take one tablet of IBRANCE, once daily for 3 weeks on and 1 week off.
What are the administration changes with IBRANCE tablets?
IBRANCE tablets can be taken with or without food and can be coadministered with PPIs or antacids. IBRANCE tablets should be swallowed whole. Patients should be advised not to crush, chew, or split the tablets before swallowing them.
Will switching from capsule to tablet change the cost of IBRANCE?
Pfizer will not be changing the cost for the new formulation. At launch, the cost for the tablet formulation will be the same as the capsules. Therefore, we do not expect the new tablet formulation to have any impact on the cost of IBRANCE to patients, access, or coverage. There are financial assistance resources available to your patients that are subject to the program's limits, terms, and conditions. Click here to learn more.
How does the packaging of IBRANCE tablets differ from the capsules?
While IBRANCE capsules were provided in bottles, the tablet formulation is dispensed in 3 weekly blister packs per month. The weekly blister packaging is designed to help patients keep track of their treatment cycles.
Can my patients still use their pill caddies for the tablet formulation?
No, patients should be advised that tablets are NOT meant to be removed from their blister packs and transferred to caddies. Patients may continue to use their pill caddies if they are still receiving IBRANCE capsules.
Are there any additional side effects or safety concerns with the IBRANCE tablets?
The efficacy and safety data in the tablet label is based on the clinical trials conducted with the capsule formulation. The benefit and risk profile of IBRANCE tablets is expected to be similar to that of the approved capsules.
How should my patients store IBRANCE tablets?
IBRANCE should be stored at 68°F to 77°F (20°C to 25°C) in the original blister pack. Patients should be advised to keep IBRANCE tablets in the blister packs.
If your patients have any questions or concerns about this formulation change, please direct them to IBRANCEtablets.com for more information.